The Mediterranean Diet (MedDiet) has been promoted as a means of preventing and treating cardiodiabesity. The aim of this study was to answer a number of key clinical questions (CQs) about the role of the MedDiet in cardiodiabesity in order to provide a framework for the development of clinical practice guidelines. A systematic review was conducted to answer five CQs formulated using the Patient, Intervention, Comparison, and Outcome (PICO) criteria. Twenty articles published between September 2013 and July 2016 were included, adding to the 37 articles from the previous review. There is a high level of evidence showing that MedDiet adherence plays a role in the primary and secondary prevention of cardiovascular disease (CVD) and improves health in overweight and obese patients. There is moderate-to-high evidence that the MedDiet prevents increases in weight and waist circumference in non-obese individuals, and improves metabolic syndrome (MetS) and reduces its incidence. Finally, there is moderate evidence that the MedDiet plays primary and secondary roles in the prevention of type 2 diabetes mellitus (T2DM). The MedDiet is effective in preventing obesity and MetS in healthy and at-risk individuals, in reducing mortality risk in overweight or obese individuals, in decreasing the incidence of T2DM and CVD in healthy individuals, and in reducing symptom severity in individuals with T2DM or CVD.
Introduction
A growing body of scientific evidence shows that the Mediterranean Diet (MedDiet) has a beneficial effect on obesity, metabolic syndrome (MetS), cardiovascular disease (CVD), and type 2 diabetes mellitus (T2DM) [1] [2] [3] [4] . These four diseases are so inherently linked that a new umbrella term, cardiodiabesity, has been adopted to reflect their coexistence and interrelationship [5, 6] (Figure 1 ). According to the International Diabetes Federation, T2DM is expected to become the seventh leading cause of death by 2030 [7] . One of the main causes of T2DM is obesity, which is now a worldwide epidemic despite efforts by the World Health Organization to meet the target of a 25% relative reduction in premature mortality from non-communicable diseases [7] . If the current trend continues, by 2025, approximately 18% of men and over 21% of women will be obese, up from the current rates of 10.8% and 14.9%, respectively [8] . The potential rise in the global incidence of cardiodiabesity is alarming, as central obesity and visceral adiposity have already been identified as causative agents of T2DM and CVD [8] .
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The word diet comes from the original Greek term diaita (way of living), and the MedDiet [9] -describing traditional dietary and lifestyle habits in the Mediterranean region-has attracted international interest as a healthy, prudent dietary pattern [10] that can, as shown by extensive evidence, contribute to the prevention of chronic diseases [11] .
Dietary recommendations can play an important role in the prevention of certain diseases. Not all physicians, however, are willing to offer nutritional advice, as they feel that they lack the necessary knowledge to confidently discuss these issues with their patients [12] . The main reasons for this reluctance include a lack of time or information, the need for cultural adaptations to dietary patterns and guidelines, and the complexity and contradictions of existing recommendations [13] [14] [15] . Even physicians themselves do not have high levels of MedDiet adherence, probably due in part to away-from-home eating, which is associated with poor health outcomes [15] . Health professionals could benefit from clinical practice guidelines (CPGs), which have been defined as recommendations developed systematically to help professionals and patients make decisions about the most appropriate health care and to select the diagnostic or therapeutic options that are best suited to addressing a health problem or a specific clinical condition [15] .
According to the Appraisal of Guidelines for Research and Evaluation (AGREE) tool, the first step in drawing up CPGs is to define a clear set of clinical questions (CQs) using the Patient, Intervention, Comparison, and Outcome (PICO) criteria [16] [17] [18] . The next step is to establish systematic and explicit criteria for reviewing and assessing the available scientific evidence to provide answers to these questions. The aim of this study was to establish a theoretical framework for the development of CPGs on the application of the MedDiet in patients with conditions grouped under the umbrella term cardiodiabesity. To do this, existing evidence on the association between MedDiet adherence and collective cardiodiabesity risk was updated [6] . The findings presented in this paper should provide experts with the basis for developing CPGs to promote the provision of evidence-based nutrition information and advice to patients with obesity, MetS, CVD, and T2DM. Summary of cardiodiabesity and standard diagnostic criteria. Cardiodiabesity encompasses cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and obesity. Note: Reproduced with permission from García-Fernández et al. [6] . Abbreviations not previously defined: HDL-Chol, high-density lipoprotein cholesterol.
According to the Appraisal of Guidelines for Research and Evaluation (AGREE) tool, the first step in drawing up CPGs is to define a clear set of clinical questions (CQs) using the Patient, Intervention, Comparison, and Outcome (PICO) criteria [16] [17] [18] . The next step is to establish systematic and explicit criteria for reviewing and assessing the available scientific evidence to provide answers to these questions. The aim of this study was to establish a theoretical framework for the development of CPGs on the application of the MedDiet in patients with conditions grouped under the umbrella term cardiodiabesity. To do this, existing evidence on the association between MedDiet adherence and collective cardiodiabesity risk was updated [6] . The findings presented in this paper should provide experts with the basis for developing CPGs to promote the provision of evidence-based nutrition information and advice to patients with obesity, MetS, CVD, and T2DM.
Materials and Methods

Literature Search
A thorough search of prospective cohort, cross-sectional, and clinical trial studies in the scientific literature was conducted to gather evidence on the ability of the MedDiet to modulate or prevent diseases encompassed by the term cardiodiabesity. Using the same search strategies as García-Fernández et al. [6] , the available evidence on the association between the MedDiet and cardiodiabesity was updated by reviewing studies published between September 2013 and July 2016. The literature search was performed in PubMed using the search term Mediterranean Diet and the key words Diabetes Mellitus, Coronary Disease, Myocardial Ischemia, Heart Disease, Metabolic Syndrome, and Obesity.
Inclusion Criteria
Five CQs were defined using the PICO framework (Table 1) [16] [17] [18] . As in the earlier review by García-Fernández et al. [6] , only those studies relating to T2DM, obesity, MetS, and CVD were eligible for inclusion. In this study, we applied more stringent selection criteria (Table 2 ) to the articles from the previous study and to the new ones. The studies included were assigned one of three levels of evidence (Table 3) to answer the formulated CQs and to establish recommendations for the CPGs. • Psychological studies in humans and meta-analyses of these • Low certainty about the estimated effects and strong likelihood that more research on the subject would alter this certainty
Low
Abbreviations not previously defined: RCT, randomized controlled trial.
The literature search was limited to human studies published in English. The search in the original review retrieved 740 articles, of which 523 were excluded based on the title. Of the remaining 217 articles, 122 were excluded after reading the abstract, and 58 after reading the full text and taking into account the selection criteria specified in Table 2 . This left 30 articles: Seven on MetS, nine on obesity, four on T2DM, and 10 on CVD [6] (Figure 2 ).
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Results
The new search retrieved 318 articles, of which 186 were excluded on screening the title. Of the remaining 132 articles, 69 were excluded after reading the abstract, and 43 after reading the full text, leaving 20 articles: Five on MetS, five on obesity, three on T2DM, and seven on CVD ( Figure 2) . Thus, the total number of articles included in the current review was 50: 30 from the original review and 20 from the updated one. Of these, 12 were on MetS, 14 on obesity, seven on T2DM, and 17 on CVD (Tables 4 and 5 ). The five CQs were addressed based on different levels of scientific evidence. The level of evidence for each question is shown below, together with the corresponding rationale. Selection process for studies included in the systematic review. The numbers in blue refer to the articles included and excluded by García-Fernández et al. [6] . The numbers in green refer to the additional articles included in and excluded from this updated review.
The new search retrieved 318 articles, of which 186 were excluded on screening the title. Of the remaining 132 articles, 69 were excluded after reading the abstract, and 43 after reading the full text, leaving 20 articles: Five on MetS, five on obesity, three on T2DM, and seven on CVD ( Figure 2) . Thus, the total number of articles included in the current review was 50: 30 from the original review and 20 from the updated one. Of these, 12 were on MetS, 14 on obesity, seven on T2DM, and 17 on CVD (Tables 4 and 5 ). The five CQs were addressed based on different levels of scientific evidence. The level of evidence for each question is shown below, together with the corresponding rationale.
CQ 1: What Effect Does the MedDiet Have on Weight Reduction in Overweight and Obese Patients?
Level of evidence: High
• MedDiet adherence reduces obesity and abdominal adiposity
Rationale: A reduction in obesity and abdominal adiposity is a well-reported effect of the MedDiet in controlled clinical trials and prospective studies. A small study in Italy showed that obese women with greater adherence to a moderately hypocaloric MedDiet experienced a significant reduction in weight and BMI (body mass index) [19] . A subsequent Croatian dietary intervention study showed that higher MedDiet adherence favored greater weight loss in obese people than a low-fat diet [20] . In Spain, several sub-studies within the PREDIMED (PREvención con DIeta MEDiterránea [Prevention with a Mediterranean Diet]) clinical trial have shown that MedDiet adherence is associated with a lower level of inflammation [21] and a greater reduction in total weight, WC (waist circumference), BMI (especially for those following a MedDiet supplemented with extra-virgin olive oil) [22, 23] , and blood pressure, as well as increased levels of high-density lipoprotein cholesterol (HDL-C) [24] .
• The MedDiet reduces CVD incidence and mortality Rationale: Until just a few years ago, the American Heart Association recommended a low-fat diet in overweight patients with high cardiovascular risk [25] . Data, however, from the PREDIMED cohort, widely demonstrated the superiority of the MedDiet in reducing CVD risk and mortality in individuals without CVD but with other baseline risk factors [26] . A systematic review by Nissensohn et al. [27] of the effects of the MedDiet and a low-fat diet also found evidence of an association between the MedDiet and a reduction in systolic and diastolic blood pressure. Higher MedDiet adherence has also been linked to a reduction in CVD risk and mortality in the general population (including obese and non-obese individuals) without CVD [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] .
CQ 2: What Effect Does the MedDiet Have on the Incidence and Prevention of T2DM?
Level of evidence: Moderate
• The MedDiet reduces the incidence of T2DM in healthy individuals
Rationale: Several studies have shown a reduction in the risk of de novo T2DM in healthy individuals with high MedDiet adherence [40] [41] [42] [43] . By contrast, a meta-analysis found no evidence of differences between the MedDiet and control diets in terms of their effect on the risk of T2DM in non-diabetic individuals [44] . Abiemo et al. [45] studied the effect of the MedDiet in the general population and found that it reduced glucose and insulin levels, but not the incidence of T2DM in non-diabetics.
• The MedDiet reduces the symptoms of T2DM and modulates disease course Rationale: MedDiet adherence has been found to reduce glycated hemoglobin (HbA1c) [43, 44] , CRP (C-reactive protein), and adiponectin [46] levels in diabetic patients.
CQ 3: What Effect Does the MedDiet Have on Established MetS or on the Risk of Developing MetS?
Level of evidence: Moderate-to-high
• High MedDiet adherence decreases some risk factors for MetS
Rationale: MedDiet adherence, compared against a control diet, has been found to reduce WC and blood pressure, and to increase HDL-C levels [24, 47] . Other studies have found no association between the MedDiet and the prevalence of MetS, although some components of the diet showed a protective effect on MetS and its components [48] .
• The MedDiet reduces some risk factors for MetS in healthy individuals Rationale: Steffen et al. [49] showed that the incidence of MetS in healthy individuals was inversely proportional to the level of MedDiet adherence. Individuals with lower adherence showed greater abdominal adiposity and a higher percentage of low HDL-C levels over a period of 25 years. Similarly, Rumawas et al. [50] reported that individuals with greater MedDiet adherence had a significantly lower incidence of MetS in addition to lower WC and triglyceride levels, and higher HDL-C levels after 7 years of follow-up. These findings were corroborated by Kess-Guyot et al. [51] . Mirmiran et al. [52] , in turn, in a prospective analysis of the MedDiet modified for the Iranian population that took into account the ratio of monounsaturated fatty acids (MUFAs) to polyunsaturated fatty acids (PUFAs) instead of olive oil consumption, found no evidence of an association between MedDiet adherence and incidence of MetS. Another prospective study by Alvarez-Leon et al. [48] , which also studied the MUFA/PUFA ratio rather than olive oil consumption, also found no association between MedDiet adherence and incidence of MetS. [28, 30, 35, 37, 39, [53] [54] [55] . Furthermore, Estruch et al. [26] showed that, compared against the low-fat diet recommended by the American Heart Association, the MedDiet supplemented with nuts or extra-virgin olive oil protected high-risk individuals from CVD. A meta-analysis of 20 studies containing data from 888,257 individuals by Grosso et al. [56] showed that increased MedDiet adherence was associated with a relative risk reduction of 40% for CVD incidence.
•
MedDiet adherence reduces CVD mortality in individuals without CVD but with high cardiovascular risk
Rationale: Several studies have reported an association between the MedDiet and a reduction in CVD mortality in individuals with risk factors for CVD [37] [38] [39] . Bonaccio et al. [38] , in turn, showed that high MedDiet adherence was associated with a relative risk reduction of 34% for CVD mortality in patients with T2DM.
• MedDiet adherence reduces CVD incidence and mortality in the general population Rationale: MedDiet intervention studies in the general population without baseline data on health status have concluded that adherence to the diet has a protective effect on CVD incidence and mortality [31] [32] [33] 36, 37, 57, 58] . A study by Fung et al. [32] of women with T2DM without a history of CVD also showed that high MedDiet adherence protected against CVD risk and associated mortality. Similarly, Knoop et al. [59] showed that higher MedDiet adherence was associated with reduced CVD-specific and all-cause mortality in the elderly population (70-90 years). [60] [61] [62] . An additional study by Paletas et al. [63] reported that MedDiet adherence contributed to weight control in individuals who were overweight at baseline. This effect was not observed for those with normal weight.
• MedDiet adherence reduces WC in the general population Rationale: Studies by Rumawas et al. [50] and Steffen et al. [49] showed that individuals with high MedDiet adherence have a smaller WC. Romaguera et al. [64] also observed this finding in individuals with a BMI between 20.09 and 20.17. MedDiet defined according to Turati [36] .
Eggs and dairy products not included. Abbreviations not previously defined: DII, dietary inflammatory index; HR, hazard ratio; CHD, coronary heart disease; ICAM, intercellular adhesion molecule; MACE, major adverse cardiovascular events; MDS, Mediterranean diet score; VCAM, vascular cell adhesion molecule; WHtR, waist to height ratio. 
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Discussion
The MedDiet is a well-known, prudent dietary pattern with health benefits supported by an exponentially increasing wealth of scientific evidence. Based on the most recent and accurate scientific evidence available, the aim of this review was to shed light on the therapeutic and preventive effects of the MedDiet on diseases encompassed by the umbrella term cardiodiabesity, in order to inform and guide the development of CPGs for physicians and health professionals. The review addressed five CQs containing key PICO components. The evidence for CQ 1 on the association between the MedDiet and improved health in overweight and obese individuals indicates that it is precisely this population that would benefit the most from the weight loss associated with the MedDiet, and from the additional benefits of a lower risk of CVD incidence and mortality. The evidence for CQ 2, regarding the potential effects of the MedDiet on T2DM incidence and prevention, was moderate. Although some studies provided solid evidence of an effect [40] [41] [42] [43] , there were discrepancies in relation to the impact of high MedDiet adherence on the risk of T2DM in healthy individuals, and to the reduction of symptoms in those who already had the disease. However, it should be noted that fewer studies have been conducted on the effect of the MedDiet-either through an intervention or simply by measuring adherence to it-on T2DM prevention or amelioration than on other cardiodiabesity outcomes. The evidence for CQ 3, on the association between the MedDiet and MetS, showed that, overall, high adherence was related to decreased risk factors for MetS. The level of evidence was moderate-to-high, although only two studies provided clear evidence of a protective effect in MetS patients. The findings relating to the risk of MetS in healthy individuals were conflicting. The answers to CQ 1 and CQ 4 indicated that overweight and obese individuals who adhered to the MedDiet were most likely to benefit from CVD prevention and disease course modulation. A reduction in CVD incidence and mortality was observed for high-risk individuals and the general population. Considering that CVD is one of the leading causes of morbidity and mortality in Western countries, a medium-term reduction in its incidence would be one of the main benefits of promoting MedDiet adherence. CQ 5 addressed the effect of the MedDiet on weight in non-overweight and non-obese individuals. The resulting evidence, graded as moderate-to-high, indicated an inverse relationship between MedDiet adherence and an increase in weight, BMI, and WC.
The evidence used to answer the five CQs was found in 50 articles from the scientific and medical literature on the association between the MedDiet and cardiodiabesity. Twenty of the articles were new and 30 were from the previous review on this topic [6] , which found strong evidence of the beneficial effects of MedDiet adherence in patients with CVD, T2DM, MetS, and obesity [6] . From the 37 articles included in the previous paper [6] , seven were excluded as they did not meet the inclusion criteria defined in this analysis. Taken together, the 50 articles show strong evidence that the MedDiet plays therapeutic and preventive roles in cardiodiabesity. There was a high level of evidence showing that MedDiet adherence improves the health of overweight and obese patients by reducing weight and WC, and lowering CVD incidence and mortality . Moderate evidence of a preventive effect of the MedDiet on T2DM was found for patients with the disease, and in individuals with and without risk factors [40] [41] [42] [43] [44] [45] [46] . Evidence of the preventive and therapeutic roles of MedDiet adherence was moderate-to-high for MetS [24, [47] [48] [49] [50] [51] [52] and high for CVD risk. Individuals with risk factors and the general population benefited from a reduction in CVD incidence and mortality [28, [30] [31] [32] [33] [35] [36] [37] [38] [39] [53] [54] [55] [56] [57] [58] [59] , thus supporting previous meta-analysis findings [57] . The association between MedDiet adherence and low weight gain, BMI, and WC in non-obese individuals was supported by low-to-high evidence [49, 50, [60] [61] [62] [63] [64] . Many mechanisms underlying the beneficial effects of the MedDiet have been described elsewhere and are mainly related to improvements in lipid profile, oxidative stress, inflammation status, glucose metabolism, vascular integrity, and effects on hormone status and gut microbiota-mediated metabolic health, amongst others [4] .
Regarding its beneficial effects on cardiovascular health, higher MedDiet adherence has been shown to improve complex processes relating to atherosclerosis, such as the atherogenicity of LDLs or the functionality of HDLs. In the latter case, this is particularly so when the MedDiet is supplemented with virgin olive oil. Epidemiological trials from the 1960s suggested that MedDiet adherence was associated with decreased rates of CVD. Many studies have demonstrated a mortality benefit from a Mediterranean or Mediterranean-like diet after MI. One example is the Lyon Diet Heart Study [67] , which showed that a MedDiet reduced recurrent cardiovascular events by 50%-70% among MI patients. However, the role of the MedDiet in the primary prevention of CVD had not been well established until the PREDIMED trial. That trial randomized 7447 Spanish patients at high risk for CVD to one of three diets: (1) A MedDiet supplemented with extra-virgin olive oil; (2) a MedDiet supplemented with nuts; or (3) a control diet encouraging the intake of low-fat foodstuffs [26] . In both MedDiet groups, there was a statistically significant reduction in the rate of the composite primary outcome of MI, stroke, or cardiovascular death after more than four years. Regarding the strength of the association, there was a 30% absolute reduction in the incidence of major CVD events in the MedDiet groups. These findings were consistent with the previous large body of observational scientific evidence, and potential confounders as alternative explanations were discarded. A dose-response gradient was observed, whereby greater MedDiet adherence showed increased protection. Every two-point increase in adherence was associated with a 25% reduction in CVD. The results were consistent with the known facts and accepted paradigms for the natural history and biology of CVD. The beneficial effects on surrogate markers of CVD risk added to the consistency. The epidemiological evidence of low CHD rates in Mediterranean countries also supports a protective effect of the MedDiet. Regarding experimental evidence, the PREDIMED RCT was intensively scrutinized in 2018 after certain comments on the randomization procedures led to the study being retracted and republished by the same research group [26, 68] . In the assessment of the quality of the RCT, inappropriate allocation concealment was among the reasons noted [69] . The authors performed several complicated analyses to attempt to control for these deficiencies, which all seemed to confirm the original findings of that study. Thus, the updated publication documented similar findings, but the authors were unable to confirm adherence to randomization schemes, given that documentation was missing (supplemental appendix of [26] ). Other high-quality dietary patterns such as the Dietary Approaches to Stop Hypertension (DASH) diet [70] and the prudent healthy pattern measured by the Healthy Eating Index [71] have also been associated with a reduced incidence of CVD events. However, the evidence collected and analyzed for these patterns is not as robust as the evidence provided by PREDIMED.
The aim of this study was to analyze the effects of the MedDiet as a diet and lifestyle, and not the effects of specific types of food. Studies focusing on the benefits of specific food groups in patients with cardiodiabesity were therefore excluded, even though some showed evidence of very strong preventive and therapeutic effects. Consumption of dairy fat, for instance, has been linked to a low incidence of MetS, while that of whole and skimmed cheese has been linked to a higher risk of MetS, and that of whole yogurt to a decrease in all the risk factors for MetS [72] . Indeed, while there have been concerns about a diet's fat content since the last century, a number of reviews have shown that a low-fat diet is not effective at preventing cardiometabolic disease [73] . A direct association has also been observed between the consumption of tea and coffee and a lower incidence of MetS within the context of the MedDiet [74] . In another study of individuals with a moderate cardiovascular risk, moderate consumers of red wine had a lower risk of MetS than non-drinkers [75] . Interestingly, this effect was more pronounced in women. The consumption of sugary drinks has been linked to increased WC [76, 77] . Mozaffarian et al. [78] conducted an in-depth review of the role of the main components of the MedDiet and other widely consumed foods in relation to health status. Their findings supported the widely agreed beneficial effects of fruit, nuts, fish, vegetables, vegetable oils, whole grains, beans, and yogurt, and the harmful effects of refined grains, starches, sugars, processed meats, high-sodium foods, and trans-fat foodstuffs. Foodstuffs for which there are still no proven beneficial or harmful effects include cheese, eggs, poultry, milk, butter, and unprocessed red meat. Albeit indirectly, the findings of this review show the benefits of the main components of the MedDiet. As called for by previous studies, the relative effects of specific food groups need further investigation [6, 55, 58, 65, 66] .
Our study has some limitations. Although some of the studies analyzed in the review did not find a strong association between MedDiet adherence and the main outcomes analyzed, they did find positive links to intermediate risk factors. Certain discrepancies could be due to numerous aspects relating to the inherent limitations of the different studies.
In addition, when analyzing the literature, it is necessary to be aware of the different confounders and indices to ensure appropriate quantitative and/or qualitative measures [79] . The likelihood of heterogeneous measures of cause and effect should also be taken into account when interpreting the association between the MedDiet and the different health outcomes, as has been done in two recent meta-analyses that corroborate the results of the PICO analysis [80] . The level of heterogeneity of the included studies is also our concern.
This study is based on the 2014 study of the association between the MedDiet and cardiodiabesity by García-Fernández et al. [6] . The literature review was updated using the same search and a similar methodology to address a series of CQs based on scientific evidence on the association between the MedDiet and cardiodiabesity, with a view to informing future CPGs on how to treat and prevent obesity, MetS, T2DM, and CVD. The evidence uncovered provides solid support of an inverse relationship between MedDiet adherence and cardiodiabesity outcomes.
Conclusions
Recent scientific evidence has shown that the MedDiet, which is listed as a UNESCO (United Nations Educational, Scientific and Cultural Organization) Intangible Cultural Heritage of Humanity [81, 82] and referred to in the 2015-2020 American dietary guidelines [83] as an example of a healthy eating pattern, has a beneficial effect on health and sustainability. It also has an important social component [84, 85] . The scientific basis for developing evidence-based CPGs consistent with international standards, such as those promoted by the Scottish Intercollegiate Guidelines Network (SIGN) and the United Kingdom's National Institute for Health and Care Excellence (NICE), has been provided. The reviewed studies show strong evidence of an association between MedDiet adherence and outcomes in cardiodiabesity, which encompasses CVD, T2DM, MetS, and obesity. The MedDiet plays a role in obesity and MetS prevention in healthy or at-risk individuals, and in mortality risk reduction in overweight or obese individuals. Furthermore, it decreases the incidence of T2DM and CVD in healthy individuals, and reduces the severity of symptoms in individuals that already have those diseases. The scientific evidence seems to support the conclusion that MedDiet adherence is a preventive and therapeutic tool for cardiodiabesity.
